The True Cost of Conducting a Global Phase 3 Pivotal Lung Cancer Clinical Trial

By Patricio Ledesma, Founder & CEO, Sofpromed

One of the most important budgeting exercises for any oncology biotech company is estimating the cost of a global Phase 3 pivotal clinical trial. 

Having supported sponsors in international oncology programs, I have found that many teams underestimate both the operational complexity and the financial investment required, particularly when overall survival endpoints are involved.

In this article, I will provide a realistic budget model for a Phase 3 pivotal lung cancer study enrolling 350 patients across 15 countries, including:

1. United States
2. Canada
3. Australia
4. Taiwan
5. Singapore
6. Japan
7. South Korea
8. United Kingdom
9. Spain
10. France
11. Italy
12. Germany
13. Slovakia
14. Greece
15. Poland

For this example, I assume:

Because this study includes a lengthy survival follow-up period and multiple regions across North America, Europe, and Asia-Pacific, the overall budget is substantial.

Executive Budget Summary

Table 1. Overall Trial Budget

For a registration-enabling global lung cancer trial, I would generally advise sponsors to budget between $115 million and $140 million.

Budget Allocation: CRO vs Pass-Through Costs

A common misconception is that CRO costs represent most of the trial budget.

In reality, site grants, imaging, central laboratories, biomarker analyses, and drug logistics usually account for the majority of spending.

Table 2. Budget Split

Typical Distribution

From my experience, pivotal oncology studies often fall within these ranges:

Detailed CRO Full-Service Budget

The following table assumes a full-service outsourcing model.

Table 3. CRO Services Budget

Detailed Pass-Through Costs

Table 4. Investigator Sites and Patient Costs

Table 5. Central Laboratory and Biomarker Costs

Lung cancer trials frequently incorporate biomarker-driven enrollment and translational medicine analyses.

Table 6. Imaging Costs

Imaging is often one of the most underestimated oncology expenses.

Site Imaging Procedures

Central Imaging Review

Total Imaging Cost

Table 7. Regulatory and Insurance Costs

Table 8. Clinical Technology Platforms

Table 9. Drug Supply Chain and Logistics

Cost by Country

Table 10. Country Allocation

Major Cost Drivers in Lung Cancer Studies

In my experience, the largest budget drivers are:

• Overall Survival Follow-Up

• 24 months of survival monitoring significantly extends staffing costs.

• Central Imaging Review

• RECIST-based endpoint adjudication can cost millions in global studies.

• Biomarker Strategy

• PD-L1, EGFR, ALK, ROS1, KRAS and NGS testing substantially increase costs.

• Japan and United States Participation

• Critical for future regulatory strategy, but among the most expensive regions.

• Monitoring Burden

• Multiregional trials with 85 sites require extensive monitoring resources.

My Top Cost-Minimization Strategies

Over the years, I have seen certain strategies consistently reduce oncology development costs while maintaining quality.

1. Select Fewer High-Recruiting Sites

An oncology site enrolling 15 patients is dramatically more efficient than three sites enrolling five patients each.

The savings include:

• Site start-up
• Contracts
• Regulatory maintenance
• Monitoring
• TMF management

Potential savings can exceed $3 million to $5 million.

2. Prioritize Strong Recruiting Countries

Countries that frequently provide excellent lung cancer enrollment performance include:

• Spain
• Poland
• Greece
• South Korea
• Italy

High-performing countries reduce timeline risk and lower overall study cost.

3. Perform Centralized Biomarker Testing

Consolidating testing through a small number of specialized laboratories reduces variability and often lowers total expenditures.

4. Use Risk-Based Monitoring

Applying ICH E6(R3) risk-based monitoring approaches can reduce monitoring costs by 15% to 25% without compromising quality.

5. Avoid Protocol Amendments

The most expensive mistake in a pivotal oncology study is often a protocol amendment.

For a trial of this size, a major amendment can easily cost:

$1 million to $5 million

through:

• site retraining
• new submissions
• revised contracts
• database updates
• delayed recruitment

6. Forecast Recruitment Monthly

I strongly recommend implementing recruitment forecasting beginning with the first enrolled patient.

Early intervention is far cheaper than launching late-stage rescue initiatives.

7. Use an Experienced Oncology CRO

Sponsors sometimes select a CRO based exclusively on price.

In my experience, oncology expertise is often far more valuable than the lowest proposal. An experienced team can prevent operational issues that ultimately cost far more than the initial savings.

How Sofpromed Supports Global Oncology Programs

At Sofpromed, we support biotechnology and pharmaceutical companies conducting multinational oncology trials through:

• Global project management
• Clinical operations
• Monitoring
• Medical monitoring
• Pharmacovigilance
• Regulatory affairs
• Data management
• Statistical programming
• Biostatistics
• Medical writing
• Vendor management
• Quality assurance

Our objective is always to improve study execution, increase recruitment efficiency, maintain high-quality data, and reduce unnecessary operational costs.

Final Summary

For a 350-patient Phase 3 pivotal lung cancer trial conducted across 15 countries over approximately 74 months, sponsors should realistically budget approximately $120 million to $130 million USD.

The biggest opportunities for cost control are not found in negotiating small line-item discounts. 

In my experience, the greatest savings come from selecting the right countries, minimizing protocol amendments, concentrating enrollment among high-performing sites, leveraging centralized biomarker testing, and partnering with experienced oncology development teams that understand the complexities of global registration-enabling studies.